PP_1170x120_10-25-21

moderate to severe vaginal dryness

Duchesnay Inc. receives approval for Osphena

Duchesnay Inc. receives approval for Osphena

BLAINVILLE, Quebec — Duchesnay Inc., a pharmaceutical company specializing in women’s health, announced today that the FDA has approved its supplemental New Drug Application (sNDA) seeking to add moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy (VVA), due to menopause, to the indication of Osphena (ospemifene). The sNDA was based on new safety and